Company: AMTX
Filing Date: 2025-02-12
Form Type: 424B5
Source: 0001437749-25-003485
Chunk: 12

Company: AEMETIS, INC
Filing Date: 2025-02-12
Form: 424B5
Chunk 12
---
 to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering. Our management may use the net proceeds for corporate purposes that may not improve our financial condition or market value. The failure by management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business and cause the price of our common stock to decline.

We may be unable to use some or all of the proceeds of this offering as intended.

Under our note facilities with Third Eye Capital, we owe approximately $208.7 million, excluding debt discounts, as of September 30, 2024. The debt agreements contain certain requirements to apply funds from equity raises to repay interest and principal, and we will require approvals from Third Eye Capital to use funds for other purposes. If the approvals are not provided, we may be required by our senior lender to use a portion or all of the net proceeds of this offering to repay our note facilities.

<div align='center'>S-9</div>

Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.

We cannot predict the effect, if any, that future issuances or sales of our common stock, preferred stock, warrants, or debt securities convertible into or exercisable or exchangeable for common stock, including sales of our common stock pursuant to the sales agreement, or the availability of our securities for future issuance or sale, will have on the market price of shares of our common stock. Issuances or sales of substantial amounts of our common stock, preferred stock, warrants, or debt securities convertible into or exercisable or exchangeable for common stock, including sales of our common stock pursuant to the sales agreement, or the perception that such issuances or sales might occur, could negatively impact the market price of our common stock and the terms upon which we may obtain additional equity financing in the future.

It is not possible to predict the actual number of shares we will sell under the sales agreement or the gross proceeds resulting from those sales. We may not have access to the full amount available under the sales agreement.

Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the distribution agent at any time throughout the term of the sales agreement. The number of shares that are sold through the distribution agent after delivering a placement notice will fluctuate based on a number of factors, including the market price of